ReviewCancer management and research2025
Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Novel Microfluidic System for Immunomagnetic Isolation of Pancreatic Cancer CTCs: Plectin‑1 and EpCAM as Potential Tumor Markers.ACS omega · 2026Article
- From imaging to omics: deep learning is bridging MRI and liquid biopsy in bone tumor diagnosis.Journal of bone oncology · 2026Review
- Early multi-cancer detection using liquid biopsy: emerging biomarkers and clinical strategies.Frontiers in oncology · 2026Review
- Circulating Tumor Cells for the Monitoring of Lung Cancer Therapies.International journal of molecular sciences · 2025Review
- Single-cell RNA-sequencing of circulating tumour cells: A practical guide to workflow and translational applications.Cancer metastasis reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most lethal malignancies worldwide, making early diagnosis and targeted treatment crucial for improving patient outcomes. Liquid biopsy, a rapidly advancing non-invasive diagnostic tool, has shown significant potential in lung cancer management through dynamic monitoring. This review explores the integration of liquid biopsy with traditional diagnostic techniques in lung cancer management. We first discuss the essential roles of traditional approaches, such as imaging and tissue biopsy, and then examine the concepts of liquid biopsy, emphasizing its unique advantages in early detection, treatment monitoring, and prognosis. Finally, we propose strategies for integrating liquid biopsy with traditional diagnostics, offering multimodal framework to enhance precision medicine in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.